|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||4.1800 - 4.1800|
|52 Week Range||0.6595 - 6.5500|
|Beta (5Y Monthly)||-2.24|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Clinical diagnostics company Novacyt - one of many healthcare companies whose shares have surged during the pandemic - announced on Monday more new products to test for the presence of the coronavirus. Novacyt said it was developing a respiratory testing panel to diagnose and distinguish between the 'A' and 'B' types of influenza, the respiratory syncytial virus (RSV) and COVID-19, with the launch of this product expected in September in time for the 2020/21 flu season in the northern hemisphere. "The immediate pipeline of new products is expected to drive incremental revenue for the company in the near-term, but Novacyt's strengthened financial position also means we are able to redefine our R&D pipeline for the next three years, which we expect to drive significant and continued growth opportunities in the longer-term," said Novacyt CEO Graham Mullis.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...